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ABSTRACT 
 
We are currently experiencing an explosive growth in data collection technology that 
threatens to dwarf the commensurate gains in computational power predicted by Moore’s 
Law. At the same time, researchers across numerous domain sciences are finding success 
using network models to represent their data. Graph algorithms are then applied to study 
the topological structure and tease out latent relationships between variables. 
Unfortunately, the problems of interest, such as finding dense subgraphs, are often the 
most difficult to solve from a computational point of view. Together, these issues 
motivate the need for novel algorithmic techniques in the study of graphs derived from 
large, complex, data sources. This dissertation describes the development and application 
of graph theoretic tools for the study of complex networks. Algorithms are presented that 
leverage efficient, exact solutions to difficult combinatorial problems for epigenetic 
biomarker detection and disease subtyping based on gene expression signatures. 
Extensive testing on publicly available data is presented supporting the efficacy of these 
approaches. To address efficient algorithm design, a study of the two core tenets of fixed 
parameter tractability (branching and kernelization) is considered in the context of a 
parallel implementation of vertex cover. Results of testing on a wide variety of graphs 
derived from both real and synthetic data are presented. It is shown that the relative 
success of kernelization versus branching is found to be largely dependent on the degree 
distribution of the graph. Throughout, an emphasis is placed upon the practicality of 
resulting implementations to advance the limits of effective computation. 
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CHAPTER ONE INTRODUCTION AND BACKGROUND 
 
Recent years have witnessed an explosive growth in the amount of raw data available for 
researchers. Access to such vast stores of data provides exciting opportunities for new 
discovery, while the very size of the datasets of interest creates ever evolving 
computational challenges. Even though growth in computing power has continued to 
observe Moore’s Law and double roughly every two years, the gains are being offset, and 
in many cases dwarfed, by a corresponding growth in data size. In fact, it was estimated 
in 2013 that 90% of the data available in the world had been generated in the two 
preceding years alone [1]. 
 
At the same time, the study of complex networks such as biological, transportation, 
social, and communication networks has become ubiquitous across the domain sciences. 
For example, network models have been used in the elucidation of putative gene 
networks [2, 3], the study of protein-protein interactions [4], examining the spread of 
influence through social networks [5], and studying the organization of the human brain 
[6]. Central to the understanding of such networks are their topological structures. As 
such, the study of complex networks is intimately interwoven with graph theory and 
graph algorithms. 
 
In the study of complex networks, we must deal with two distinct hurdles. First, we are 
faced with the ever-increasing rate of growth of available data sets. The second, and 
perhaps more insidious challenge, is that the problems we often wish to solve are among 
the most difficult from a computational point of view. For example, the problem of 
finding the maximum clique in a graph, its largest fully connected subgraph, is in fact 
NP-complete. Overcoming these difficulties will require the use of novel algorithmic 
techniques such as Fixed Parameter Tractability (FPT) and the development of scalable 
parallel solutions. 
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The primary focus of this dissertation is the development of novel graph-theoretical 
approaches utilizing exact solutions for classical NP-complete problems to analyze the 
structure of complex networks. The specific settings considered in chapters two and three 
are from the biological sciences, but the applications transfer easily to other domains. To 
address the computational challenges the quest for such exact solutions impose, chapter 
four investigates the relative importance of the two key components of a parallel FPT 
implementation of vertex cover – kernelization and branching. Finally, chapter five 
summarizes the results and main contributions, as well as suggesting some avenues for 
further research. 
 
Data Types 
Gene Expression 
 
The history of modern DNA microarrays traces back to the colony hybridization method 
of Grunstein and Hogness in 1975 [7]. In the roughly four decades since, microarray 
technologies have proven to play a central role in advancing biological research. 
Microarrays measure gene expression levels using chips with a set of hybridization 
probes designed to target and bond to a specific sequence of mRNA. The technology has 
advanced to the point that platforms such as the Affymetrix Exon 1.0 ST array are 
capable of exon level resolution of expression with approximately 1.4 million probesets 
comprised of over 5 million individual probes. For an excellent review of the history, 
types, and applications of DNA microarrays see [8]. 
 
Epigenetic Data 
 
When the Human Genome Project undertook its mission to map the entire DNA sequence 
of the human genome in 1990, it carried the hope of transforming our understanding of 
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biology. In 2001 it was even chronicled in an episode of NOVA on PBS entitled 
“Cracking the Code of Life [9].” While certainly representing a great leap forward in our 
fundamental knowledge of genetics, it has become clear since its completion in 2003 that 
there are mechanisms at play in the actual expression of genes that go far beyond the 
physical arrangement of the underlying genetic code. These discoveries have led to the 
establishment of a new branch of research – epigenetics. This fledgling field was defined 
in 1990 by Robin Holiday as “the study of the mechanisms of temporal and spatial 
control of gene activity during the development of complex organisms [10].” In recent 
years, however, there has been some disagreement over whether the definition of an 
epigenetic trait should be limited to those that are heritable [11]. 
 
A variety of epigenetic mechanisms have been discovered. Two of the major classes of 
epigenetic modifications are DNA methylation and histone modification. 
 
DNA methylation generally occurs when a methyl group is added at the 5’ position of the 
cytosine ring, transforming the cytosine to 5-methylcytosine. Usually this occurs at CpG 
dinucleotides, although non-CpG methylation has been seen to occur more frequently in 
specific contexts such as neural development and in embryonic stem cells [12]. The 
process is believed to be regulated by DNA methyltransferases including DNMT1, 
DMNT3a, and DMNT3b. DNMT1 works to maintain methylation patterns by 
recognizing and copying them to the unmethylated daughter strands during DNA 
replication. DNMT3a and DMNT3b are thought to be responsible for de novo 
methylation events. Mutations in the DNMT3b gene have been found to be responsible 
for ICF (Immunodeficiency, centromeric instability, facial anomalies) syndrome [13], 
while mutations to any of DNMT1, DNMT3a, or DNMT3b have been found to be 
embryonically lethal in mice [14, 15].  
 
In humans, some 70% of CpG dinucleotides throughout the genome are methylated [16]. 
At the same time, there are genomic regions with a heavy concentration of CpG content 
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that can be found in the promoter regions of many genes. The cytosines in these CpG rich 
regions, termed CpG islands, tend normally to be unmethylated with exceptions in the 
context of the inactive X chromosome [17] and imprinted genes [18, 19]. Aberrant 
methylation patterns have been found to play a role in many diseases. In particular, it has 
been shown to play a dual role in many forms of cancer through both a pattern of global 
hypomethylation, allowing aberrant overexpression and ensuing oncogenesis, together 
with hypermethylation of CpG islands in the promoter regions of tumor suppressor genes, 
leading to their silencing [20-22]. 
 
Histone acetylation occurs when an acetyl group is added to the NH3+ group on Lysine. 
The process takes place at the N-terminal of histone tails. Acetylation and deacetylation 
are generally catalyzed by histone acetyltransferase (HAT) or histone deacetylase 
(HDAC) enzymes respectively. Acetylation acts to transform the overall positive charge 
of the histone tail to neutral, weakening the binding of the nucleosomal components and 
making the DNA more accessible to transcriptional agents. Thus, hyperacetylation is 
positively correlated with actively transcribed genes. 
 
The lysine and arginine residues of the histone tails can be methylated, but it is most 
commonly observed on the lysine residues of the tails of H3 and H4. Lysine can be 
mono-, di-, or trimethylated with a methyl group replacing a hydrogen of its NH3+ 
group. Arginine has a free NH2 and NH2+ group and can be mono- or dimethylated. A 
demethylation of arginine can occur on a single group, or with an asymmetric 
methylation of each group. 
 
Although DNA methylation and histone modifications are perhaps the most studied and 
well known epigenetic mechanisms, a vast amount of ongoing research is also being 
invested in other post-translational modifications such as phosphorylation, ubiquitination, 
and somoylation. 
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Other Amenable Data Types 
 
While the applications we consider in the next two chapters are drawn from the biological 
domain, our methods are based on abstract models. As such, they can be applied to 
virtually any type of data that admits such a model. The only requirements are that there 
must be some entities that can be represented by nodes and we must be able to calculate 
some similarity metric between them. Data can be continuous like the biological data 
already considered, or categorical. For example, other work at the Langston Lab has used 
graph algorithms to examine categorical data from the health disparities domain [23]. 
 
Translation to Graphs 
Creation of Graphs 
 
In seeking to analyze vast networks, we model the interactions as a graph so that we can 
apply graph algorithms to better our understanding of the latent relationships. Nodes can 
then be used to represent entities of interest, be they genes in a gene network, proteins in 
a protein-protein interaction network, locations in a transportation network, or people in a 
social network. In order to model the relationships between the actors represented by the 
nodes, we must have some concept of how to place edges between them. In some 
contexts, this is as straightforward as connecting “related” nodes, such as placing edges 
between nodes in a social network if the people they represent are acquaintances or 
between nodes in a road network if the locations they represent are connected by a road. 
In others, we need a more mathematical or technical idea of a similarity measure such as 
correlation coefficients or Jaccard similarity. 
 
In the context of gene expression networks, we often build graphs with nodes 
representing individual genes. Pearson correlation coefficients are then calculated for 
each pair of genes taken across the measures for each sample. An edge is then placed 
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connecting the nodes if the correlation level (in absolute value) exceeds some 
thresholding value. 
 
Thresholding 
 
There are a variety of methods that can be employed to select a suitable threshold value 
to use. Often times, we may use methods based on experimentation. For example, when 
building graphs for a paraclique analysis as in [24, 25], we may build a series of graphs 
that gradually reduce the threshold until we encounter an inflection point in the number 
of paracliques produced. Another approach is to use the spectral method introduced in 
[26], which uses the eigenstructure of the adjacency matrix. 
 
Relevant Graph Theory and Algorithms 
Notations 
 
A graph is an abstract representation of a network consisting of a set of vertices and a set 
of edges that connect pairs of vertices. Formally, a graph 𝐺𝐺(𝑉𝑉,𝐸𝐸) consists of a vertex set 
𝑉𝑉 and an edge set 𝐸𝐸 containing ordered pairs of vertices from 𝑉𝑉 such that (𝑢𝑢, 𝑣𝑣) ∈ 𝐸𝐸 
indicates the presence of an edge between 𝑢𝑢 and 𝑣𝑣. A graph is said to be simple if it 
contains no self-loops or multiple edges. That is to say, there is no vertex with an edge 
back to itself, and there is at most one edge connecting any particular pair of vertices. A 
graph can be weighted by adding weight properties to its vertices, its edges, or both. In 
this dissertation, all graphs considered are simple, finite, undirected and unweighted 
unless explicitly noted otherwise. 
  
7 
 
A pair of vertices 𝑢𝑢 and 𝑣𝑣 are said to be adjacent if (𝑢𝑢, 𝑣𝑣) ∈ 𝐸𝐸. The size, or order, of a 
graph is taken to be its number of vertices, |𝑉𝑉|. The degree of a vertex 𝑣𝑣 is the number of 
vertices to which 𝑣𝑣 is adjacent, or equivalently, the number of edges with 𝑣𝑣 as an 
endpoint. The neighborhood of a vertex 𝑣𝑣 in 𝐺𝐺, denoted by 𝑁𝑁𝐺𝐺(𝑣𝑣) or, when the graph is 
clear in context simply by 𝑁𝑁(𝑣𝑣), is the set of vertices that are adjacent to 𝑣𝑣. A subgraph 
of a graph 𝐺𝐺(𝑉𝑉,𝐸𝐸) is a graph 𝐺𝐺′(𝑉𝑉′,𝐸𝐸′) such that  𝑉𝑉′ ⊆ 𝑉𝑉 and  𝐸𝐸′ ⊆ 𝐸𝐸, with the 
requirement that if (𝑢𝑢′, 𝑣𝑣′) ∈ 𝐸𝐸′ , both 𝑢𝑢′ and 𝑣𝑣′ belong to 𝑉𝑉′. A subset of vertices can be 
used to identify a subgraph of 𝐺𝐺 called an induced subgraph. An induced subgraph 
contains the inducing vertices as its vertex set, and all the edges between those vertices 
that were present in 𝐺𝐺. The complement of a graph 𝐺𝐺, denoted ?̅?𝐺, is formed by removing 
the existing edges, and adding those that were not originally present. Examples of an 
induced subgraph and the complement of a graph can be seen in figure 1. 
 
 
 
 
Figure 1. Induced subgraphs and graph complements. Suppose 𝐺𝐺 is the graph shown in 
(a). Then (b) is its subgraph induced by the set of vertices {1,3,4,6}, and (c) is ?̅?𝐺, its 
complement. 
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The Clique Problem and the Paraclique Algorithm 
 
A clique in a graph is a fully connected subgraph. In other words, a clique is simply a 
subgraph containing all of its possible edges. The usual notation for a clique with 𝑛𝑛 
vertices is 𝐾𝐾𝑛𝑛. An example of a 𝐾𝐾5 can be seen in figure 2. 
 
The identification of cliques has found a wide variety of applications, from identifying 
putative gene pathways [27] to detecting collusive trading patterns in the stock market 
[28]. The maximum clique problem is one of the most studied in graph theory. The 
decision version, simply deciding if a graph contains a clique of a given input size, is one 
of the original 21 NP-complete problems listed in Karp’s seminal work [29]. 
 
In practice, focusing solely on searching for cliques often proves too stringent a 
requirement. The presence of noise in real world data often leads to missing edges in our 
graphs. As the loss of even a single edge destroys a clique, such noise results in a higher 
than desirable number of false negatives when examining the data for signal. 
 
 
 
Figure 2.  𝐾𝐾5, a clique on 5 vertices. 
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In order to provide more robust resistance to the effects of noise, the paraclique algorithm 
was introduced in [25]. The basic idea is that we start with a maximum clique and grow it 
to a paraclique by successively adding in, or glomming onto, vertices that are adjacent to 
all but some acceptable number of vertices present at the current stage. The number of 
edges allowed to be missed at each iteration is governed by a constant called the glom 
term. An example of a paraclique can be seen in figure 3. 
 
The paraclique algorithm has proven to be highly effective, and shown to outperform 
other popular clustering techniques in terms of density and ontological enrichment [30]. 
Although most of the work involving the algorithm has to this point focused on its 
application, theoretical work can be found in [25, 31]. 
 
The Dominating Set Problem 
 
We can speak of both edge-dominating and vertex-dominating sets for a graph G. In this 
dissertation, by a dominating set, we will mean a vertex-dominating set, that is, a subset S 
of the vertex set V such that for every v in V, either v is in S or at least one of its 
neighbors is in S. In particular, we will be interested in a variant of Dominating Set, 
namely Red-Blue Dominating Set, in which the nodes of a graph are colored either red or 
blue and we seek the smallest set of red vertices that dominate all the blue vertices (or 
vice versa). See figure 4 for an example. 
 
Fixed Parameter Tractability 
 
In the past few decades, fixed parameter tractability has emerged as a powerful approach 
to the design and implementation of practical algorithms for solving problems once 
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Figure 3. An example of a paraclique. This example was produced with glom term g=2 
from a maximum clique of size four {1,2,3,4} (a) and progressively adding vertices 5 (b), 
6 (c), and 7 (d). 
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Figure 4. An example of red-blue dominating set. A minimum red-blue dominating set is 
formed by the set of vertices {1,4}. Note that any such set must contain vertex 4 as it is 
the only one to cover vertex 6. The covering edges as highlighted for clarity. 
 
 
deemed hopelessly intractable. The origins of FPT trace back at least to the foundational 
work of Fellows and Langston in the area of well-quasi-orderings and nonconstructive 
tools for proving polynomial time computability [32-34]. Around the same time, 
Robertson and Seymour proved the graph minor theorem, showing that undirected graphs 
are well-quasi-ordered under the graph minor relationship [35]. These results provided 
the impetus for the establishment of a new area of research, which would be termed Fixed 
Parameter Tractability, in the seminal work by Downey and Fellows [36]. 
 
One goal of FPT is to provide a more fine-grained approach to classifying the difficulty 
of a problem than that taken in classical complexity theory. Not all NP-complete 
problems are created equally after all, and perhaps even more importantly, some 
“difficult” problems may be solved very quickly in practice if we are only interested in 
solutions of a particular size. The central idea is that if there is some parameter k in the 
problem that, when held fixed, will allow the problem to be solved in time with any 
super-exponential dependence being only in k, then the problem is in the class FPT. In  
other words, a problem is FPT if it can be solved in time 𝑂𝑂(𝑓𝑓(𝑘𝑘)𝑛𝑛𝑐𝑐) where n is the 
problem size, k is an input parameter, and c is a constant independent of both k and n. 
12 
 
There are two core tenets to Fixed Parameter Tractability – kernelization and branching. 
Kernelization refers to a process of reducing the problem size to a compute kernel whose 
size depends only on the fixed parameter k. This reduction must also be doable in 
polynomial time with regards to the problem size. In [37] it is shown that a problem 
being kernelizable is in fact equivalent to it being FPT. 
 
Once the problem has been reduced to a compute-intensive kernel, it remains to explore 
the resulting reduced search space. Various branching techniques aim to explore this 
space as efficiently as possible. Whereas kernelization techniques aim to reduce the 
impact of the original problem size in algorithm runtimes, improved branching aims to 
reduce the remaining, often exponential, dependence on the size of the parameter k. 
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CHAPTER TWO NOVEL ALGORITHMIC DEVELOPMENT: 
EPIGENETIC BIOMARKER DISCOVERY 
        
In this chapter, we investigate the use of a combination of statistical scoring methods 
with a red-blue dominating set filter for the elucidation of novel methylation biomarkers. 
Parts of the material in this section have appeared previously in preliminary form in 
posters or in papers currently submitted for publication. These will be cited as such 
wherever appropriate. 
 
Introduction and Overview of Methods 
 
Previous work in the Langston Lab has produced innovative graph-theoretical tools for 
mining gene co-expression data for transcriptomic biomarkers. In this study, we 
investigate extensions and applications of these tools to the analysis of differential DNA 
methylation data. Sites are scored with a statistical metric that gauges their potential 
effectiveness for separating case data from control. Results are then filtered using red 
blue dominating set. Inter-sample scores are calculated for sites passing this filter using a 
custom scoring function that, based on site quality, favors homogeneous case-case and 
control-control pairs over case-control pairs. This general line of research can be traced 
back to the seminal toolchain first employed in [39]. 
 
Site Merit Scores 
 
To begin, each methylation site is assigned a merit score by means of the following 
function: 
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠) = |𝜇𝜇𝑖𝑖(𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠) − 𝜇𝜇𝑖𝑖(𝑠𝑠𝑠𝑠𝑛𝑛𝑠𝑠𝑠𝑠𝑠𝑠𝑐𝑐)| − 𝛼𝛼|𝜎𝜎𝑖𝑖(𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠) + 𝜎𝜎𝑖𝑖(𝑠𝑠𝑠𝑠𝑛𝑛𝑠𝑠𝑠𝑠𝑠𝑠𝑐𝑐)| 
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Where 𝜇𝜇𝑖𝑖 and 𝜎𝜎𝑖𝑖 are the mean and standard deviations, respectively, of the indicated 
sample group and 𝛼𝛼 is a constant used as a tuning factor with 0 < 𝛼𝛼 ≤ 1. We start with 
𝛼𝛼 = 1 and adjust it downward as necessary until we are able to identify sites with 
positive merit scores. 
 
Inter-sample Discrimination Scores 
 
Ultimately the goal is to be able to identify sites that are capable of providing a clean 
separation between case and control. To that end, we next calculate inter-sample scores. 
The score comparing sample 𝑠𝑠 and sample 𝑗𝑗 is assigned via: 
 
∑𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑘𝑘) ∙ �1 − �𝑚𝑚𝑠𝑠𝑠𝑠ℎ𝑦𝑦𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛_𝑣𝑣𝑐𝑐𝑐𝑐𝑢𝑢𝑠𝑠𝑖𝑖𝑖𝑖 − 𝑚𝑚𝑠𝑠𝑠𝑠ℎ𝑦𝑦𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠𝑛𝑛_𝑣𝑣𝑐𝑐𝑐𝑐𝑢𝑢𝑠𝑠𝑗𝑗𝑖𝑖��. 
 
This metric is designed in such a way so as to favor homogeneous over heterogeneous 
sample pairs. Thus, case-case pairs and control-control matched pairs will tend to receive 
higher scores than mismatched case-control pairs. Presented with an unknown sample, 
the user can then compute its scores against the training set and classify it based on the 
group to which it most closely aligns. 
 
Dominating Set Filter 
 
Our scoring function has the potential to return a large number of sites with positive merit 
scores. In practice, we would like to be able to winnow these sites down to those with the 
best potential as discriminatory markers. In such situations, we apply a filter based on 
red-blue dominating set.  
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We first construct a bipartite graph with sites as red vertices forming one partite set and 
samples as blue vertices in the other. For each site, we calculate the p-value of its 
observed methylation level for each sample. This p-value is calculated in the distribution 
of the levels at that site across all the group samples of the same type, be it case or 
control. A site is said to cover a sample and an edge is added between them in the graph 
if the p-value is greater than .05. This culls from the tails of the distributions and leaves 
us with observed methylation values that are in some sense “normal” for the sample 
within its group at each site. 
 
Unfortunately, a straight application of minimum dominating set might sacrifice sites 
with high merit scores for those with lower discriminatory power based solely on the size 
of the returned set. To guard against this, we begin with the top scoring site and 
iteratively add the next highest scoring until the set built up forms a dominating set. We 
then take a minimum set from among this collection. 
 
In order to visualize the effectiveness of our reduced set in discriminating between case 
and control samples, we examine the distribution of the inter-sample scores. Presented 
with an unknown sample, we could then compute its scores against the training set and 
classify it based on which group it most closely aligns. That is, if it scores highly against 
case, with lower scores against control, it would be classified as case and vice-versa. 
 
Application: Biomarker Discovery in Human Disease 
 
Parts of this section have appeared in preliminary form in the following research poster: 
“Methylation Biomarker Discovery in Age-Related Diseases”, Ronald D. Hagan, Michael 
A. Langston, Keystone Symposia Conference on Epigenetic Aging and Aging Related 
Diseases, May 1-May 5, 2016, Santa Fe, New Mexico. 
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Age is the single greatest risk known for developing a host of diseases including cancer, 
dementia and osteoarthritis. Recent research has shown that epigenetic mechanisms too 
seem to play a key role in these afflictions. Aberrant DNA methylation patterns in 
particular have been associated with nearly all forms of human cancer. These discoveries 
provide a compelling impetus for the development of methods for the discovery of novel 
methylation biomarkers capable of differentiating between healthy and diseased states. 
Such markers could then potentially be used in screening and diagnosis, and as guides for 
the selection of therapeutic targets for DNA-demethylating agents. 
  
We applied our method to eight sets of publicly available data obtained from GEO, the 
Gene Expression Omnibus. These sets were chosen to span a variety of diseases, have a 
relatively large number of case and control samples, and to come from a common 
platform. All the sets are from the Illumina Infinium HumanMethylation450 BeadChip 
array, often referred to as the Illumina 450k methylation array. The data sets are 
summarized in Table 1.  
 
Osteoarthritis 
 
According to the Arthritis Foundation, osteoarthritis is the most common chronic 
condition of the joints. Sometimes called degenerative joint disease, it has no specific 
cause, but is influenced by several factors including age, occupation, obesity, injury and 
overuse. As well as having a known genetic component, several studies have been 
conducted that point to epigenetic mechanisms such as DNA methylation [40, 41] and 
histone modifications [42, 43]. The GEO series GSE63695 consists of methylation data 
from chondrocyte DNA samples drawn from the hip cartilage of 23 patients with 
osteoarthritis, knee cartilage of 73 osteoarthritis patients, and 21 hip samples from 
healthy controls. For the purpose of this study, we discarded the data from the knee 
cartilage in order to avoid possible confounding issues due to a mixture of tissue types. 
17 
 
 
 
 
 
 
 
Table 1. An overview of our methylation datasets. All sets consist of publicly available 
data obtained from GEO – the Gene Expression Omnibus. 
 
GEO Series Number Disease Case Samples Control Samples 
GSE63695 Osteoarthritis 23 21 
GSE66695 Breast Cancer 80 40 
GSE54503 Liver Cancer 66 66 
GSE61107 Schizophrenia 24 24 
GSE52588 Down Syndrome 29 29 
GSE40360 Multiple Sclerosis 28 19 
GSE62003 Dementia in T2D 18 18 
GSE75679 Sjogren’s Syndrome 24 24 
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With α = 1, we identified 777 sites with positive merit scores for separation. The top 
scoring sites mapped to the genes ALX4, ANK1, and ARNT2. Differential expression of, 
or differential methylation in the promoter regions for, each of these genes has been 
indicated in the literature as playing a role in the development of osteoarthritis [44-46]. 
 
Our dominating set filter identified a set of three methylation sites that covered all 
samples. As seen in Figure 5, the homogeneous sample pairs clearly  
cluster toward the high end of the inter-sample scores giving a nice separation and a 
classifier built to train on the data using our three sites should perform rather well. 
 
In order to verify our hypothesis, we used the Multi-layer Perceptron model available in 
the scikit-learn python package to construct a fully connected artificial neural net with 
three hidden layers as illustrated in Figure 6. Using our three sites as the feature set, we 
then conduct five-fold cross validation testing on the data set. For this Osteoarthritis data, 
we obtained a mean accuracy of 0.89 indicating that our selected sites are indeed 
effective for the purpose of classification. 
 
Breast Cancer 
 
Breast cancer in women accounts for one in ten of all new cancers diagnosed worldwide 
annually [47]. As with all cancers, DNA methylation is known to play a large role in its 
progression. A host of studies have been undertaken in efforts to improve our 
understanding of that relationship. For example, see [48-50]. Series GSE66695 consists 
of methylation data drawn from 40 normal and 80 breast cancer tissue samples. 
 
In the breast cancer data, our scoring metric produced 12,107 sites with positive merit 
scores for 𝛼𝛼 = 1. The top scoring sites mapped to ZFP106, MXRA7, and the tumor 
suppressor gene ST7. MXRA7 has been found to be differentially expressed in a number  
19 
 
 
Figure 5. Distribution of Osteoarthritis inter-sample scores. 
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Figure 6. A fully connected neural network with three inputs and three hidden layers. The 
input layer consists of a set of neurons {x1, x2, x3} representing the input features. Each 
neuron in the hidden layers applies a weighted linear transform, followed by a nonlinear 
activation function to the values it receives and feeds the result forward through the 
network. From the results of the final hidden layer, the output layer calculates a result 
classifying the original input. 
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of cancers [51]. We were able to uncover a dominating set consisting of five sites 
separating the data. The distribution of inter-sample scores shows a near total separation 
of the homogeneous and heterogeneous sample pairs, lending strong evidence to support 
the utility of our five sites as biomarkers for breast cancer. See Figure 7. 
 
Once again we went a step further, seeking to validate our method using an artificial 
neural net. Using scikit-learn once again with the same configuration as for the 
osteoarthritis data, we used the five sites identified by our dominating set reduction as 
features and conducted five-fold cross validation. In this case, we achieved a mean 
accuracy of 0.96, strongly supporting our conclusions and also providing good anecdotal 
evidence that the better the visual separation in the distribution of inter-sample scores, the 
better the performance of the identified sites as features for classification. 
 
 
 
Figure 7. Distribution of Breast Cancer inter-sample scores. 
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Liver Cancer 
 
The most common type of primary liver cancer is hepatocellular carcinoma or HCC. It 
ranks as the fifth most common type of cancer globally and is responsible for the third  
most deaths due to cancers. Despite its high global rankings, the distribution of cases is 
strongly centred in sub-Saharan Africa and Eastern Asia with China accounting for more 
than 50% of all cases worldwide [52]. GSE54503 is made up of methylation data drawn 
from 66 pairs of hepatocellular carcinoma (HCC) liver tumors and adjacent non-tumor 
tissues. 
 
With 𝛼𝛼 = 1, our scoring produced a set of 30,576 methylation sites having positive merit 
scores. Dominating set filtering produced a set of four probes covering all samples. These 
sites map to the genes KCNQ2, C1orf70, GRASP, and PTPRN2. All four can be found in 
the literature as being involved in HCC, see [53-55]. As can be seen in Figure 8, the 
distribution of inter-sample scores again provides a nearly ideal separation between like 
and mixed sample pairs. 
 
 
Figure 8. Distribution of HCC inter-sample scores. 
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Schizophrenia 
 
GSE61107 comes from a genome-wide methylation analysis of brain tissue in 
schizophrenia patients [56]. It is made up of data drawn from frontal cortex post-mortem  
tissue from 24 individuals diagnosed with schizophrenia and 24 controls. The tissue 
samples themselves were provided by the Human Brain and Spinal Fluid Resource 
Centre. 
 
With 𝛼𝛼 = 1, only four sites were identified with positive merit scores. Three of these 
sites mapped to TNRC6C, ZNF787, and HOXA13, while the fourth mapped to an 
intragenic region on chromosome 6. HOXA13 appears repeatedly as a potential 
biomarker for schizophrenia in the literature. See for example [57-59]. While the 
separation we obtain in this case is not to the level observed with the cancer datasets, we 
still observe a marked upshift in the distribution of homogeneous inter-sample scores as 
can be seen in Figure 9. 
 
Down Syndrome 
 
GEO series GSE52588 arises from a study aiming to identify a DNA methylation 
signature of Down Syndrome in whole blood cells [60]. Data comes from whole 
peripheral blood samples taken from 29 subjects affected by Down Syndrome as well as 
29 matched samples taken from healthy familial controls (either mothers or unaffected 
siblings). 
 
While the cause of Down Syndrome is established as a trisomy of chromosome 21, the 
underlying mechanisms influencing the variety of physical and mental manifestations of 
the phenotype are largely unknown. Perhaps unsurprisingly, recent research has begun to  
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Figure 9. Distribution of Schizophrenia inter-sample scores. 
 
 
 
show a strong link to global patterns of aberrant methylation [61]. It has even been 
suggested that methylation biomarkers could form the basis for non-invasive prenatal 
screening [62]. 
 
With 𝛼𝛼 = 1, we initially obtained 2897 sites with positive merit scores. Interestingly, 
only 42 of these sites map to chromosome 21. As can be seen in figure 10, these sites 
produce a perfect separation between like and unlike sample pairs. 
Multiple Sclerosis 
 
GSE40360 originated from a study seeking to identify differences in methylation patterns 
in pathology-free regions of brain tissue in persons affected by multiple sclerosis [63]. 
Drawn from brain bank samples of normal appearing white matter dissected from the 
frontal lobe, it consists of post-mortem samples from 28 multiple sclerosis patients as 
well as 19 healthy controls. This particular set turned out to be quite dirty, with numerous  
0
10
20
30
40
50
60
70
0.
01
7
0.
01
7
0.
01
8
0.
01
8
0.
01
9
0.
01
9
0.
01
9
0.
02
0
0.
02
0
0.
02
1
0.
02
1
0.
02
2
0.
02
2
0.
02
3
0.
02
3
0.
02
4
0.
02
4
Sa
m
pl
e 
Pa
irs
Inter-Sample Scores
Schizophrenia
normal-normal
scz-scz
scz-normal
24 
 
 
Figure 10. Distribution of Down Syndrome inter-sample scores. 
 
 
missing values. As such, an initial preprocessing step was required. We chose to discard 
records for all probes missing entries for a sample, leaving us with data for 460,421 
probes. 
 
This is our first dataset that returned no positive scores for a tuning factor of 1. Reducing 
to 𝛼𝛼 = 0.9, we obtained a set of seven sites with positive merit scores. As can be seen in 
figure 11, we start to see a decreased separation in the distribution commiserate with the 
need to lower 𝛼𝛼. Notice however, that the homogeneous sample pairs still produce scores 
that fall primarily in the top third of the distribution. 
Dementia in Type 2 Diabetes 
 
Along with the primary challenges associated with their disease, those suffering from 
Type 2 Diabetes are at elevated risks for a host of other maladies including Alzheimer’s 
disease. GSE62003 is taken from a study looking for methylation signatures  
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Figure 11. Distribution of Multiple Sclerosis inter-sample scores. 
 
 
differentiating between risk for developing dementia in elderly T2D patients [64]. It 
consists of data taken from peripheral blood samples drawn from 18 individuals with 
T2D who developed pre-symptomatic dementia within 18 months of undergoing a 
baseline assessment and 18 controls who maintained normal cognitive function. Samples 
are matched based on age, sex and education. 
 
Initially we were unable to produce sites with a positive merit score for separation. 
Reducing the tuning factor to 𝛼𝛼 = 0.8 produced 14 such sites. A look at the distribution 
of inter-sample scores in figure 12 again shows a pattern that, while providing a less ideal 
separation than observed in some previous cases, clearly segregates the majority of 
homogeneous sample pairs into the top third. 
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Figure 12. Distribution of inter-sample scores for dementia in Type 2 Diabetes. 
 
 
Sjogren’s Syndrome 
 
Sjogren’s syndrome is a systemic autoimmune disorder that affects the entire body, but 
generally presents initially by attacking the moisture producing glands of the eyes and 
mouth. Among the many possible complications for those suffering from primary 
Sjogren’s syndrome (pSS) is background chronic fatigue. In [65], the authors study 
methylation patterns associated with such concurrent fatigue. The associated dataset, 
GSE75679, consists of methylation data measured in whole blood samples from 24 pSS 
patients with high fatigue and 24 identified as low fatigue. 
 
Once again, the initial run identified no sites having positive merit scores. Dropping the 
tuning factor to 𝛼𝛼 = 0.7 produced eight sites. As can be seen in figure 13, in this case we 
observed a distinctive comingling of the homogeneous and heterogeneous inter-sample  
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Figure 13. Distribution of inter-sample scores for chronic fatigue in Sjogren’s. 
 
 
 
scores. This leads us to believe that methylation based biomarkers might not be feasible 
for identification of susceptibility to chronic fatigue in Sjogren’s Syndrome, at least not 
when drawn from peripheral whole blood. 
Summary and Discussion 
 
Ongoing research by the biological community has established that epigenetic 
mechanisms play a central role in the development of a variety of human diseases, 
including most known forms of cancer. In this study, we examined the extension of a 
method previously developed for biomarker discovery in gene expression data to a 
similar role for use with DNA methylation data. Using a combination of statistical 
scoring functions and graph-theoretical based filtering methods, our methods identify a 
set of methylation sites that are putatively best suited to distinguish between case and 
control samples. 
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We applied our methods to eight publicly available data sets obtained from the Gene 
Expression Omnibus that together represent a broad cross-section of human disease. Each 
set consists of both case and associated control samples. Our results show that our 
methods have great promise in successfully identifying sets of putative biomarkers. 
Beyond visual validation via observable separations in the distributions of inter-sample 
scores, we also tested two of our resultant sets for efficacy as feature sets in the 
construction of artificial neural network models. These models show the capacity for a 
high degree of fidelity. Using five-fold cross validation we obtained mean accuracies of 
0.96 and 0.89 for models for breast cancer and osteoarthritis respectively. 
 
 
Application: Obesity Related Biomarkers for Adipose Tissue 
Differentiation 
 
Most of this section has appeared previously in either a joint paper submitted for 
publication: “Genome-wide DNA Methylation Analysis Reveals Loci that Distinguish 
Different Types of Adipose Tissue in Obese Individuals”, Donia Macartney-Coxson, 
Miles C. Benton, Ray Blick, Richard S. Stibs, Ronald D. Hagan, Michael A. Langston 
or in preliminary form in the poster: “Adipose Tissue DNA Methylation Markers 
Associated with Weight-loss and Tissue Specificity”, Donia Macartney-Coxson, Miles 
Benton, Alice Johnstone, Richard Stubbs, Ronald D. Hagan, Michael A. Langston, 
Keystone Symposia Conference on Epigenetic Programming and Inheritance, April 6 – 
April 10, 2014, Boston, Massachusetts. 
 
My contributions include running experiments, enhancing our biomarker toolchain, 
preparing figures, and writing up the results. 
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Background 
 
 In humans, white adipose tissue consists of two main types, subcutaneous and visceral 
(including omentum), that are distributed throughout the body in distinct depots. 
Mitochondria rich brown adipose tissue depots, on the other hand, were once thought to 
be found only in early development. Recent studies, however, have found higher than 
expected levels of such depots in adults [66-68]. White adipose tissue can also undergo a 
process of ‘browning’ or ‘beiging’ [69, 70]. Each of these types of adipose tissues have 
distinct structural and biochemical properties [71-73], and both body fat distribution and 
function influence metabolic risk [74-81]. Various studies have been undertaken 
investigating the different developmental origins of subcutaneous and visceral adipose 
tissue based on gene expression [73, 82-84], with recent evidence suggesting a 
mesothelial origin for visceral adipose [85]. In addition, studies have begun to focus on 
the role of DNA methylation in the differentiation and development of the various types 
of adipose tissue [86, 87]. 
 
My co-authors previously performed DNA methylation analyses of paired subcutaneous 
and omental adipose from obese individuals undergoing gastric bypass, seeking to 
identify within-tissue differences before and after significant weight-loss (defined as a 
subject losing more than 27% of their initial weight) [88]. In the current study, we 
compare methylation levels between subcutaneous adipose and omentum tissue in an 
effort to identify methylation biomarkers suitable for differentiating between the tissue 
types both before and after weight-loss. 
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Identification of Tissue Differentiation Markers 
 
Applying our tools to the pre-operative samples produced 4900 CpG sites, mapping to 
2309 genes, with positive merit scores for separating adipose tissue types and passing 
initial filtering. As can be seen in figure 14, the distribution of inter-sample scores using 
all 4900 sites produces an appealing, but not quite complete, separation of the tissues. For 
the post-operative group, we identified 8624 CpG sites, mapping to 4066 genes, such 
sites having positive merit scores. Once again, the identified sites produce an attractive 
separation of tissue types, see figure 15. Of the sites identified in the two groups of 
samples, 1022 produced positive merit scores for separation at both time points (pre- and 
post-operative).  
 
 
 
Figure 14. Distribution of inter-sample scores for pre-operative tissue differentiation 
using all 4900 sites with positive merit scores. Here and in the following figures legends, 
omental tissue is denoted Om while subcutaneous adipose tissue is denoted by Ab. 
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Figure 15. Distribution of inter-sample scores for post-operative tissue differentiation 
using all 8624 sites with positive merit scores 
 
 
Our initial analysis considered all sites with positive merit scores. As an ideal biomarker 
panel would include the fewest markers needed for clean separation between case and 
control groups, we examined the discriminatory power of a reduced number of sites at 
each time point. We found that using only the 10 highest ranked sites was sufficient to  
obtain good separation between the tissue types for both the before and after weight-loss 
groups, see figure 16 and 17, respectively. We then reduced to the top scoring site for 
each group. While a single site did not perform as well in the pre-operative group, we 
found that the top site provided full discriminatory power in the post-operative samples. 
See figures 18 and 19. An overview of the ten highest ranked sites at each time point can 
be seen in Table 2. 
 
Validation of Tissue Differentiation Markers 
 
We performed a technical validation of our observations using pyrosequencing of robust 
tissue discriminators from each analysis, i.e. the top 10 ranking sites from the before  
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Figure 16. Distribution of inter-sample scores for pre-operative tissue differentiation 
using the ten sites with highest merit scores. 
 
 
 
 
Figure 17. Distribution of inter-sample scores for post-operative tissue differentiation 
using the ten sites with highest merit scores. 
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Figure 18. Distribution of inter-sample scores for pre-operative tissue differentiation 
using the single site with the highest merit score. 
 
 
 
Figure 19. Distribution of inter-sample scores for post-operative tissue differentiation 
using the single site with the highest merit score. 
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Table 2. Top 10 CpG sites ranked by merit score. 
Illumina 
probe ID 
Mean beta AB 
(+/- standard 
deviation) 
Mean beta OM 
(+/- standard 
deviation) 
UCSC 
Gene Name 
CpG site 
chromosome 
and position+ 
Before 
weight-loss 
analysis 
    
cg02245004 0.12 (+/- 0.08) 0.64 (+/- 0.11) Intergenic 15:76634887 
cg03923561 0.45 (+/- 0.07) 0.04 (+/- 0.02) HOXC4 12:54447220 
cg22747076 0.42 (+/- 0.09 0.02 (+/- 0.02) HOXC4 12:54447873 
cg09400037 0.42 (+/- 0.06) 0.82 (+/- 0.07) Intergenic 16:84822801 
cg24376776 0.03 (+/- 0.01) 0.33 (+/- 0.03) Intergenic 10:101297245 
cg11797364 0.59 (+/- 0.1) 0.97 (+/- 0.02) Intergenic 6:436969 
cg17496661 0.65 (+/- 0.08) 0.99 (+/- 0.01) Intergenic 5:3326343 
cg09720701 0.37 (+/- 0.05) 0.06 (+/- 0.01) HOXC4 12:54447283 
cg02264990 0.35 (+/- 0.06) 0.03 (+/- 0.02) HOXC4 12:54447243 
cg01524853 0.43 (+/- 0.05) 0.12 (+/- 0.03) HOXC4 12:54447807 
     
After weight-
loss analysis 
    
cg00838040 0.34 (+/- 0.07) 0.97 (+/- 0.03) ATP2C2 16:84446919 
cg21917524 0.31 (+/- 0.07) 0.81 (+/- 0.04) Intergenic 11:74200334 
cg24145118 0.84 (+/- 0.07) 0.31 (+/- 0.16) Intergenic 10:2777041 
cg12984729 0.09 (+/- 0.03) 0.59 (+/- 0.16) ISL2 15:76633817 
cg12437821 0.46 (+/- 0.04) 0.05 (+/- 0.09) Intergenic 12:114852027 
cg01184975 0.53 (+/- 0.05) 0.10 (+/- 0.11) Intergenic 12:114852091 
cg20291855 0.03 (+/- 0.03) 0.44 (+/- 0.11) Intergenic 4:13524143 
cg25365014 0.79 (+/- 0.05) 0.41 (+/- 0.05) Intergenic 5:2727713 
cg16297011 0.07 (+/- 0.04) 0.48 (+/- 0.11) Intergenic 4:13539023 
cg21982455 0.56 (+/- 0.04) 0.19 (+/- 0.07) Intergenic 5:2757976 
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weight-loss and the top site from the after weight-loss analyses. This revealed an 
excellent agreement between the two methylation assays; before weight-loss (R2 = 0.91-
0.98, P = 1.2x10-15–8.3x10-25), and the single site after weight-loss (R2 = 0.97, P = 4.9 x 
10-14).  
 
Next, we sought to test the performance of our candidate biomarkers in additional, 
independent samples. DNA was available for a further 15 individuals before weight-loss 
and 13 of these 15 individuals after weight-loss. Principal component analysis (PCA) 
revealed a strong agreement between the discovery and validation samples for the before  
weight-loss comparison, with no significant variation observed between genders in the 
validation samples as can be seen in figure 20. 
 
 
 
Figure 20. PCA analysis of the top 10 CpG sites from the before weight-loss tissue 
samples. Analysis was performed on pyrosequence data. Tissue type is indicated by OM 
(omentum) and subcutaneous abdominal adipose (AB), with Dis indicating the discovery 
and Val the validation samples. 
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We were able to obtain publicly available Illumina 450K data for a number of adipose 
samples. Samples accessible through MARMAL-AID [89] included samples from 6 lean 
male individuals with both subcutaneous and omental adipose tissue collected ≤ 12h post-
mortem (GSE48472 [90]), 14 visceral adipose samples from severely obese men, 7 of 
which had metabolic syndrome (GSE54776 [91]), as well as 6 paired subcutaneous 
adipose and gluteal adipose samples from lean females (GSE47513 [86]). Illumina 450K 
data was also available for 642 subcutaneous adipose samples from individuals with an 
average BMI of 26.7 (and a standard deviation of 4.9) [92] from the MuTHER (multiple 
tissue human expression resource) project [93]. In examining the methylation profile of 
all 11 strong discriminators from the before and after weight-loss groups in these publicly 
available datasets, we observed good agreement within a tissue type irrespective of 
gender and/or obesity phenotype.  
 
In general, omental samples showed a tighter distribution of methylation for a given 
probe than the subcutaneous adipose samples, and for the majority of probes a strongly 
hyper-methylated (mean methylation beta >0.8, cg00838040, cg17496661, cg17496661) 
or hypo-methylated (mean methylation beta <0.2, cg09720701, cg02264990, 
cg22747076, cg03923561, cg22747076) phenotype. Given that the biomarker analysis 
was trained on data from subcutaneous and omental adipose it is interesting to note that 
the samples of subcutaneous gluteal adipose tissue from lean females showed a 
methylation profile similar to that of the subcutaneous abdominal adipose samples and 
clearly distinct from the omental samples. 
 
Summary and Discussion 
 
In this study, we applied our methylation biomarker tools to isolate CpG sites capable of 
differentiating between white adipose tissue in human subjects both before and after 
undergoing gastric bypass surgery. We identified a large set of sites with positive merit 
37 
 
scores that we filtered to reveal 10 CpG sites before weight-loss and a single site after 
weight-loss that strongly separated the tissue types. Additional confidence in our results 
is provided by an excellent overlap between the pyrosequence methylation profiles of the 
11 CpG sites in the discovery and validation cohorts and from publicly available 
subcutaneous and omental adipose Illumina 450K data from lean, overweight and obese 
individuals.  
 
While there is no clinical utility in a marker to differentiate subcutaneous and omental 
adipose, this study provides further support for the potential of DNA methylation as a 
biomarker. Combined with the promising results of our work with disease data described 
in the previous section, we believe future work to translate our combinatorial approach to 
the detection of clinically applicable DNA methylation biomarkers is warranted, and may 
have particular merit for situations in which robust differentiators are still urgently 
required. Furthermore, because epigenetic mechanisms are dynamic and as such 
potentially reversible, these types of analyses may also highlight innovative new avenues 
for clinical treatment. Such analyses should take account of practicability concerns such 
as ease of sample/tissue collection, and whether there is a biological argument for 
potential DNA methylation differences between sample groups.  
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CHAPTER THREE NOVEL ALGORITHMIC DEVELOPMENT: 
SUBTYPING 
 
In this chapter, we turn to gene co-expression data and the development of a method 
based on the paraclique algorithm to identify unknown subtypes in human disease. A 
portion of the material in this section appear in [94]. My contributions to this paper 
include algorithm development, data aggregation, and experimentation and document 
preparation. 
 
Introduction 
 
The ability to identify disease subtypes accurately and efficiently is a central pursuit in 
the drive to individualized medicine. In the case of cancer patients, knowledge of a 
genetic propensity towards chemo-resistance or towards early response can be used to 
tailor treatment to be more, or less, aggressive. Early responders, for example, might 
require less aggressive treatment, mitigating the long-term risks of adverse effects of 
radiation therapy or chemotherapy associated toxicity. For example, studies have 
identified gene expression signatures for chemo-resistance in both acute myeloid 
leukemia and breast cancer [95, 96].  
 
While techniques grounded in graph theory have been used to great effect in the pursuit 
of genetic biomarkers for human disease and the discovery of novel gene networks, little 
work has been done in trying to extend such tools to subtyping. The existing research has 
primarily centered on the use of basic statistical or machine learning clustering methods 
such as k-means, latent variable models, or mixture models [97-99].  
 
Clique-centric methods have often been used for the discovery and modeling of coherent 
networks. Unfortunately, clique finders are inherently prone to high false negative rates. 
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Indeed, an entire clique will be lost if even a single edge is missing. The paraclique 
algorithm was introduced to address the difficulties presented by signal loss due to noise 
in the data. While paracliques can be constructed in different ways, the basic idea is to 
take a maximum clique as a core, then expand it to a paraclique by adding vertices 
adjacent to all but some allowable number g of its vertices. 
 
Here, we present a method for subtyping based on the paraclique algorithm. The 
remainder of this chapter is organized as follows. An overview of our method and the 
data sets initially used for experimentation are provided in the next section. We then 
discuss the initial validation testing and examine additional steps taken to verify the 
biological relevance of our results. Finally, we provide avenues for continued research. 
 
Methods and Data 
 
 In an effort to limit the effects of confounding factors, we use an initial filtering step. 
FDR corrected p-values for differential expression of genes between case and control sets 
are calculated, and only those with p-values less than 0.1 are retained. The idea being that 
this technique will limit our attention to those genes of interest only in the case group. 
After all, we are not interested in subgroups based on age, ethnicity, or hair color. The p-
values are calculated using the EntropyExplorer R package [100]. After filtering, the data 
tables are transposed and we calculate the pairwise Pearson correlation coefficients 
between samples across the expression levels. Thresholding the correlation matrix, we 
then create an unweighted graph with vertices representing individual samples and edges 
between vertices if the corresponding samples are correlated above the thresholding level 
(in absolute value). Once the graph is built, we run the paraclique algorithm to extract 
dense subgraphs of patients representing putative subtypes in the case samples. Finally, 
we separate the groups, return the tables to their original configuration, and calculate 
differential expression across subtypes. Here, the level of differential expression is taken 
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to be simply the difference in the mean expression levels between the groups. An 
overview of our method can be found in Figure 21. 
 
We initially applied or methods to 12 sets of publicly available gene expression data 
obtained from the Gene Expression Omnibus (GEO). The data sets were selected to 
provide a wide cross-section of human disease and to have information on both a case 
and control group for initial filtering. Table 3 gives an overview of the datasets used. 
 
Initial Validation and Discussion 
 
Our investigation into the effectiveness of our proposed method was focused on two 
guiding questions. First, is the method capable of reliably identifying putative subtypes? 
Second, is there biological evidence confirming or at least supporting these subtypes as 
being biologically relevant to the associated disease? 
 
We found that the answer to the first question is unequivocally yes. As summarized in 
Table 4, we found putative subtypes in 10 of our datasets. In the other two cases, we 
hypothesize that our method fails due to limiting conditions present in the data. First, the 
sizes of the datasets are relatively small (only 10 samples in both cases) and may not give 
a true representation of the underlying populations. Secondly, the disease in question 
might not have meaningful subtypes based on differential gene expression. 
 
The second question is considerably more difficult to answer. In order to address it, we 
followed a two-prong approach in examining the top differentially expressed genes 
between subgroups. To begin, we calculated the GO enrichments of the top 100 genes  
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Preprocessing
Graph Creation Metric: sample-sample 
correlations 
Paraclique Extraction
Putative Subgroups
 
Figure 21. Suptyping method overview. A greatly simplified view of our subtyping 
workflow. Gene expression data is preprocessed with an initial filtering step. A graph is 
created using the pairwise sample correlation scores taken across the expression scores. 
Paracliques are then extracted that represent putative subtypes. 
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Table 3. Subtyping datasets. An overview of the datasets used in this study. 
Disease 
GEO 
Accession 
Probes 
Probes After 
Filtering 
Case Control 
Asthma GSE4302 54675 2322 42 28 
Breast Cancer GSE10810 18382 11531 31 27 
CLL GSE8835 22283 1338 24 12 
Colorectal Cancer GSE9348 54675 22968 70 12 
Lung Cancer GSE7670 22283 7458 27 27 
Multiple Sclerosis GDS3920 54674 9844 14 15 
Pancreatic Cancer GDS4102 54613 23711 36 16 
Parkinson’s  GSE20141 54674 6625 10 8 
Prostate Cancer GSE6919 12625 1531 61 63 
Psoriasis GSE13355 54675 29407 58 58 
Schizophrenia GSE17612 54675 4250 28 23 
T2 Diabetes GSE20966 61294 93 10 10 
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Table 4. Subgroups identified. Summary of the number and sizes of putative subgroups 
identified by our methods in the test data. 
 
Disease Number of Subgroups 
Identified 
Size of Subgroups 
Identified 
Asthma 2 32,8 
Breast Cancer 2 22,5 
CLL 2 4,18 
Colorectal Cancer 2 63,5 
Lung Cancer 2 21,5 
Multiple Sclerosis 2 11,3 
Pancreatic Cancer 2 31,5 
Parkinson’s 1 8 
Prostate Cancer 2 56,3 
Psoriasis 2 49,5 
Schizophrenia 2 19,6 
T2 Diabetes 1 9 
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and the associated enrichment p-value. The results, along with the associated enriched 
GO categories, are summarized in Table 5. We next performed a literature search to 
check the lists of the top genes for involvement in known subtypes. We were able to find 
strong empirical evidence to support having successfully identified known groups in four 
of our datasets: Asthma, Breast Cancer, CLL, and Colorectal Cancer. Before we go 
further, let us look at these four cases in more detail. 
 
Asthma 
 
The incidence of asthma in the U.S has been on the rise for two decades. It is currently 
estimated that 9.6% of children under 18 are asthmatic, with the risks for some groups 
based on ethnicity (particularly African American and Puerto Rican) and stratification by 
lower socioeconomic status rising as high as 16% [101]. 
 
The GEO series GSE4302 is derived from a study designed to identify genes associated 
with response in asthmatics to treatment with corticosteroids [102]. It consists of 
expression data derived from epithelial airway brushings taken from 42 asthmatics and a 
control group consisting of 28 healthy subjects and 16 smokers. For our analysis, we used 
only the healthy subjects as control, discarding the smokers. Data is derived from a 
microarray analysis using the Affymetrix Human Genome U133 Plus 2.0 Array. 
 
Our initial filtering step reduced the original 54,676 probes to a set of 2322 having FDR 
corrected p-values < 0.1 for differential expression between the case and control groups. 
With the reduced set of variables and a threshold of 0.93, our method produced three 
putative subgroups of size 31,8, and 3. The 100 most differentially expressed genes 
between the groups included CLCA1, periostin, and ovalbumin. All three of these genes 
were reported in [103] to be markers of a Th2-high endotype of asthma. 
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Table 5. GO enrichment. The GO term category with the lowest p-value for the 
enrichment of the 100 most differentially expressed genes across identified subgroups. 
 
Data Set Category p-value 
Asthma GSE4302 Oxireductase 1.1E-4 
Breast Cancer GSE10810 Secreted 1.0E-13 
CLL GSE8835 Mhc ii 2.4E-15 
Colorectal Cancer GSE9348 Translational elongation 2.8E-28 
Lung Cancer GSE7670 Secreted 7.7E-10 
Multiple Sclerosis GDS3920 Translational elongation 1.9E-34 
Pancreatic Cancer GDS4102 Signal 4.59E-15 
Prostate Cancer GSE6919 Translational elongation 4.92E-46 
Psoriasis GSE13355 Immune response 3.5E-15 
Schizophrenia GSE17612 Organelle membrane 5.24E-4 
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Breast Cancer 
 
Genetic factors have long been known to play a significant role in breast cancer. In 
families that have had at least 4 cases of breast cancer, studies have shown the majority 
of cases can be linked to mutations in either BRCA1 or BRCA2 genes [104, 105]. In 
addition, breast cancer has a variety of known subtypes that significantly impact 
prognosis and treatment. For example, tumors negative for estrogen receptors, 
progesterone receptors, and the expression of HER2 are indicative of triple-negative 
breast cancer, a subtype identified with higher risk of recurrence and 5-year mortality 
[106]. 
 
GSE10810 comes from a study aiming to investigate more fully the links between gene 
expression and phenotypic differences in breast cancer [107]. It consists of gene 
expression data for 31 tumor samples and a control set of 27 healthy tissue samples. The 
platform used for the study was again the Affymetrix Human Genome U133 Plus 2.0 
Array, although only data for 18,382 probes was provided. 
 
The number of probes was reduced to 11,531 with false discovery rate adjusted p-values 
for differential expression between the case and control groups < 0.1. Using a threshold 
of 0.8, our tools produced 2 putative subgroups of size 22 and 5. The 100 most 
differentially expressed genes between these subgroups include SLC39A6, S100a4, 
AGR3, Cd24, and epcam. All of these genes have been reported in the literature as being 
markers for different phenotypes of breast cancer [108-112]. 
 
Chronic Lymphocytic Leukemia 
 
Chronic Lymphocytic Leukemia (CLL) is one of the most common types of leukemia 
with pathogenesis presenting as an overproduction of neoplastic B cells in the 
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bloodstream. The median age at diagnosis is 65, and more commonly affects males [113]. 
It typically presents with a slow progression, with patients living out a normal life 
expectancy. In some cases, however, it can be aggressive, with death occurring less than 
5 years after onset. 
 
The dataset GSE8835 was provided by a study with the aim of examining the effects of 
CLL on the expression levels in peripheral blood T cells [114]. It is made up of 24 CD4 
cell samples from CLL patients and a control group of 12 CD4 cell samples from healthy, 
age matched donors. The Affymetrix Human Genome U133A Array with 22,283 probes 
was used. 
 
Filtering reduced the initial probes to a set of 1338 having p-values less than 0.1 (again 
FDR corrected). A threshold of 0.8 produced two subgroups of size 4 and 18. The most 
differentially expressed genes across the two groups included ZAP-70, previously 
identified as the best discriminator of Ig-mutated and Ig-unmutated CLL [115]. 
 
Colorectal Cancer 
 
The incidence of colorectal cancer (CRC) has been in decline since the mid 1980’s [116]. 
Despite this significant drop in prevalence, it still annually accounts for both the third 
highest number of new cases of cancer, and the third highest number of cancer deaths 
[117]. As in breast cancer, there are known hereditary links to CRC. For example, a 
mutation of the gene APC is responsible for two syndromes, Familial Adenomatous 
Polyposis and Hereditary Nonpolyposis Colorectal Cancer, that each carry a significant 
increase in the risk of developing CRC [118]. 
 
GSE9348 was derived from a study aiming to find a gene expression signature for cases 
of early stage CRC that are prone to metastasis [119]. It consists of gene expression data 
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derived from tumors of 70 patients and tissue from 12 healthy controls. The samples are 
age and ethnicity matched. The study utilized the Affymetrix U133 Plus 2 array. 
 
Our filtering reduced the 54675 probes in the original set to 22968 with FDR corrected p-
values < 0.1 for differential expression between the case and control groups. With a 
threshold of 0.87, our tools produced two paracliques representing putative subgroups in 
the tumor samples of size 63 and 5. The list of 100 genes most differentially expressed 
between these two groups include Cd24, identified as a prognostic marker for CRC [120] 
as well as OLFM4, indicated in as a marker for tumor differentiation and progression 
[121, 122]. 
 
Further Validation: Testing with Known Subtypes 
 
While our initial validation efforts indicate that our methods indeed have the potential to 
identify both known and novel subtypes based on biologically relevant genetic signatures, 
the lack of an established ground truth is a distinct limitation for our testing. In order to 
address this point, we identified two additional sets of publicly available data on GEO 
that included labeling for membership into distinct subtypes. The goal of course being to 
apply our tools in a search for evidence that we could identify subgroups appropriately 
stratifying the samples. 
 
Gastric Cancer 
 
The first set is GSE35809, consisting of gene expression data from 70 primary gastric 
tumors used as a validation set for testing of a classifier for tumor subtypes [123-125]. 
The samples are identified in the data as belonging to one of three subtypes: proliferative, 
invasive, or metabolic. The number of samples for each type in the original data are 29, 
26, and 15 respectively. 
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As this set does not contain accompanying control data, we forgo the initial filtering 
phase. Applying the remainder of our toolchain and using a threshold of 0.955, we 
identified two subgroups that, while both contained a mixture of metabolic tumors, nearly 
perfectly segregated the invasive and proliferative types. See Table 6. 
   
Non-Small Cell Lung Cancer 
 
Non-small cell lung cancer, or NSCLC, has two major known subtypes – 
adenocarcinoma (AC), and squamous cell carcinoma (SCC). GSE10245 is made up of 
gene expression data for 40 adenocarcinoma, and 18 squamous cell carcinoma NSCLC 
tumors and was provided from a study examining differential expression between the two 
types [126]. 
 
 
 
Table 6. Known subtype results. A breakdown of the composition of the subtypes 
obtained from the cases with included subtype labeling. In both cases, we obtained 
putative subgraphs that cleanly segregated the samples according to subtype. 
 
Gastric Cancer NSCLC 
 Paraclique Sizes  Paraclique Sizes 
 29 16   26 12 8 
Subtype    Subtype    
proliferative 1 12  AC 23 0 8 
invasive 19 1  SCC 3 12 0 
metabolic 9 3      
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Once again, the set lacks control data, so the initial filtering must be skipped. For this 
dataset, our tools, with a threshold of 0.94, identifies 3 putative subgroups that show a 
remarkable separation between the subtypes. Referring once again to Table 6, we see that 
two of the three groups are completely homogeneous, while the third consists of 23 AC 
tumors with a crossover of only 3 SCCs. 
 
Subtyping Summary 
 
In this chapter, we have described a method based on the paraclique algorithm to identify 
putative subtypes separating samples based on signatures in their gene expression 
profiles. We applied our methods to a variety of publicly available data starting with 12 
sets obtained from the Gene Expression Omnibus. Of those 12, our tools identified 
putative subtypes for 10. We sought to validate the relevance of our findings by 
reviewing the literature and examining the GO enrichment for biological relevance of 
genes differentially expressed across our potential subtypes. We also performed 
additional testing with two sets data containing phenotypic information for known 
subtypes, also obtained from GEO. The results of our testing indicate a strong potential 
for our approach to be highly effective in the discovery of novel subtypes. 
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CHAPTER FOUR CRITICAL ALGORITHMIC ANALYSIS:  
KERNELIZATION VERSUS BRANCHING 
 
 
 
Most of this chapter appeared previously in [127]. My contributions include 
implementing the full degree 2 rule, collecting testbed graphs, running experiments and 
writing the paper. 
 
In this chapter, we investigate the relative significance of kernelization versus branching 
for parallel FPT implementations. Using the well-known vertex cover problem as a 
familiar example, we build and experiment with a testbed of five different classes of 
difficult graphs. For some, we find that kernelization alone obviates the need for 
parallelism. For others, we show that kernelization and branching work in synergy to 
produce efficient implementations. And yet for others, kernelization fails completely, 
leaving branching to solve the entire problem. Structural graph properties are studied in 
an effort to explicate this trichotomy. The NP-completeness of vertex cover makes 
scalability an extreme challenge.  
 
Introduction 
 
Fixed-Parameter Tractability (FPT) has become a popular and powerful technique for 
dealing with the recalcitrance of NP-completeness. An amenable problem is FPT if it has 
an algorithm that runs in O(f(k)nc) time, where n is the problem size, k is the input 
parameter, and c is a constant independent of n and k. Representative citations include 
[36] for theoretical development, [128] for previous work on parallel implementations, 
and [129] for historical perspective. 
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Vertex cover is probably the best known and most widely studied FPT problem. In its 
usual decision formulation, we are given a simple undirected graph G of order n and an 
integer k, and asked whether G contains a set S of at most k vertices so that every edge in 
G has at least one endpoint in S. Minimum vertex cover and its complementary dual, 
maximum clique, are highly appreciated for both their prominence in complexity theory 
and their wealth of practical applications. 
 
Two tenets of FPT are kernelization, in which an input of size n is reduced to a compute 
core whose size depends only on k, and branching, whereby an efficient tree structure is 
used to explore the solution space. It would not be a gross oversimplification to say that 
kernelization is generally fast, while branching is not. That some part of the solution 
process is slow and exhaustive should not come as a surprise. After all, we are trying to 
solve enormous NP-complete problems exactly. On the other hand, the relative speed of 
kernelization should not belie its importance. Only by reducing the problem size 
dramatically can we hope for runtimes polynomial in n. 
 
In recent work [130], it has been shown that one can often obtain excellent parallel 
speedup on large-scale biological graphs, as primarily derived from transcriptomic data. 
These sorts of graphs tend to be relatively sparse, more or less scale free, and contain 
many highly overlapping cliques of various sizes. It was found that kernelization and 
branching tend to work together quite well for these types of inputs. Methods were in fact 
often interleaved [131]. 
 
In this chapter, we study these and other input domains in an effort to elucidate the 
relative significance of kernelization versus branching and the need for parallel FPT 
computation. To this end, we use reasonably straightforward sequential and parallel FPT 
vertex cover implementations and examine performance on large graphs of five general 
classes: physical infrastructure, social interaction, high-throughput biological, pseudo-
random, and regularly structured. Despite their notoriety, we find that infrastructure and 
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social graphs tend to succumb to mere kernelization. Biological graphs, meanwhile, 
benefit from both kernelization and branching. On the other hand, regularly structured 
and, to a lesser extent, pseudo-random graphs tend to be resistant to kernelization. Thus 
they benefit from highly efficient branching, parallelized implementations and effective 
load balancing strategies. 
 
In the next two sections, we detail important relevant features of kernelization and 
branching. Section 4 contains descriptions and discussions of the various sources and 
sorts of domain data we use in this study. We also present sample timings for each. In 
Sections 5 and 6 we analyze these results and discuss directions for future study. 
 
Kernelization Rules 
 
Let us briefly review standard vertex cover kernelization reductions. The easiest to apply 
are the low degree rule, the high degree rule, and the degree two rule. It is noteworthy 
that the high degree rule alone ensures an O(k2) kernel. Given G, n and k, we iteratively 
apply these rules, at each stage creating a new graph G′ with n′ ≤ n and k′ ≤ k. 
 
The Low Degree Rule: Any isolated vertex cannot cover any edges and may be 
removed, reducing n′ by 1. In the case of a vertex of degree one, we can cover no fewer 
edges by discarding it and removing its parent and putting it in the cover. This reduces n′ 
by 2 and k′ by 1. 
 
The High Degree Rule: If a vertex has degree greater than k then it must be included in 
an acceptable cover. Otherwise there would be at least k+1 edges, which could only be 
covered by including all its neighbors. Removing such a vertex and putting it in the cover 
reduces n′ by 1 and k′ by 1. 
 
54 
 
The Degree Two Rule: This rule is considerably more complicated. There are two 
separate cases to consider. Suppose u has degree two, with neighbors v and w. 
 
Case 1: v and w are neighbors. In this case, at least two of u, v, and w must be included in 
any satisfying cover in order to account for the edges of the triangle they form. Including 
u would cover only two edges, while v and w both cover at least two and possibly more. 
Thus, we are best served by removing all three vertices and including v and w in the 
cover. This reduces n′ by 3 and k′ by 2. 
 
Case 2: v and w are not neighbors. In this case, we form G′ by folding u, v, and w into a 
new vertex, u′, whose neighborhood consists of the union of the other neighbors of v and 
w. It turns out that G′ contains a vertex cover of size k′ = k – 1 if and only if G contains a 
vertex cover of size k. See Figure 22 for an example. (For completeness, we note that 
there are actually two options. If the cover of G′ contains u′, then v and w will be in the 
cover for G while u may be discarded. If the cover of G′ does not contain u′, then u will 
be in the cover for G while v and w may be discarded. With either option, n′ is reduced by 
2 and k′ is reduced by 1. The specific option to choose is only relevant in backtracking, 
when solving the search not the decision version of the problem.) 
 
After applying these rules, we have reduced our original question of the existence of a 
cover for G of size no more than k to the search for a cover of G′ of size less than or equal 
to k′. 
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Figure 22. Kernelization. An example of Case 2 of the degree two rule. Vertices u, v, and 
w are folded into u′. 
 
  
56 
 
Branching Strategies 
 
After kernelization, we are left with the computationally imposing task of exploring a 
search space whose size is exponential in k. The best current theoretical running time can 
be found in [132]. There, a limit of O(1.2738k + kn) is achieved, but at the cost of  
excruciating branching techniques, some of which may actually work against us on 
average. Thus, we employ instead a relatively simple search tree strategy to traverse the 
possible covers. At each level in the tree, we choose the vertex, v, of highest degree and 
branch in two directions. For the left branch, we add v to the candidate cover. For the 
right branch, we discard v and place all of v’s neighbors in the cover. This 
straightforward but easily parallelized technique is illustrated in Figure 23. 
 
The search along each branch proceeds until either k vertices have been added to the 
candidate solution or all edges are covered. At that point, the validity of the cover is 
checked. If a satisfying cover has indeed been found, then all search paths are terminated 
and we return a “yes” decision. On the other hand, if the candidate cover is not a 
satisfying cover, then branching must continue until we find a solution or exhaust the 
search space. At each branching stage, we include at least one more vertex in the 
candidate solution. Thus, this process results in a search tree of depth bounded by k. 
Kernelization times are generally insignificant. Branching tends to be exhaustive, 
however, and so it is the usual focus for parallel FPT speedups. 
 
Each branching path reduces graph size and complexity. It is therefore sometimes 
possible to re-kernelize at branch points. We use this technique, known as interleaving 
[133], in our implementations in an effort to reduce overall run times and enhance 
parallel speedups. 
 
 
 
57 
 
 
 
 
 
Figure 23. Branching. Dark vertices are placed into a candidate cover. 
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For parallel implementations, we perform search tree decomposition in MPI, using a 
master-slave paradigm. Each processor is initially assigned an independent branch to 
search. Without some form of load balancing, however, a processor may starve should it 
finish its branch early. Thus, we employ dynamic load balancing to keep all processors 
busy. Our approach designates a highest degree branch as a donor. When any branch 
completes, it receives additional work from the donor. Should the donor itself terminate 
early, a new donor is selected again based on highest degree. For a thorough description 
of the approach and an analysis of its effectiveness, see [128, 130]. 
 
Data and Experiments 
 
Large-scale experiments were conducted on DOE’s Hopper supercomputer, named after 
the remarkable computing pioneer Admiral Grace Murray Hopper. Part of the National 
Energy Research Scientific Computing (NERSC) Center, the Hopper platform was 
ranked 16th fastest in the world according to the TOP500 list for June, 2012. It is a 
CrayXE6 system rated at a peak speed of 1.28 PetaFLOPS, which it attains with 6,384 
nodes made up of two 2.1 GHz twelve-core AMD ‘MagnyCours’ processors, for a total 
of 153,216 compute cores. Hopper is maintained at the Lawrence Berkeley National 
Laboratory. 
 
We sought to test graphs from a broad variety of application domains. Our interest 
focused on finding graphs that are enormous and/or difficult enough to pose a challenge, 
even for our streamlined vertex cover FPT implementations. The graphs we selected fall 
into five general categories: physical infrastructure, social interaction, high-throughput 
biological, pseudo-random, and regularly structured. Three representative graphs were 
selected from each class. For each such graph, we computed the minimum vertex cover in 
the complement, and employed a simple binary search to determine the optimum 
parameter value. To identify the hardest instances, we report timings for the largest “no” 
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parameter value. (Had we used instead the smallest “yes” value, runs could have 
encountered a satisfying solution early, biasing the results, whereas a “no” instance must 
exhaust the entire search tree.) Every graph was sequentially kernelized. As expected, no 
bottleneck was encountered during this process. Branching was performed sequentially 
and, when sequential times were sizable, in parallel. For standard comparisons, all 
parallel runs were timed on 24 cores. 
 
Physical Infrastructure Graphs 
 
We were able to obtain large-scale connectivity information on road systems, airport 
networks and power grids. The Road Graph comes to us from California. Its vertices 
denote intersections and destinations. Its edges represent connections between these sites. 
The Airport Graph is based on direct flight connectivity in the United States. The Power 
Graph was obtained from the high voltage power grid for the western states. All three sets 
of data were obtained from the Stanford Large Network Dataset Collection. 
 
Both the Road Graph and the Airport Graph produce very small kernels, which complete 
branching in under a hundredth of a second. The Power Graph was solved completely 
through kernelization, requiring no branching whatsoever. We note that our physical 
infrastructure graphs have modest clique sizes and low average degree, and many of their 
cliques are disjoint. Therefore, the high degree rule applies to many vertices in their 
complements. The graphs are rapidly decomposed almost entirely. This sort of 
algorithmic behavior highlights the power of kernelization, and eliminates the need for 
heavyweight computations during branching. See Table 7. 
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Table 7. Computational experience with large physical infrastructure graphs. Run times 
are reported in seconds. The graph derived from power networks was solved completely 
during kernelization, and thus needed no branching at all. 
 
Graph Road Airport Power 
|V| 30000 1858 4941 
|E| 87628 17215 6594 
Density 0.00019 0.00998 0.00054 
Kernel Size 147 126 7 
Clique Size 3 56 6 
Sequential Branching  0.00363 0.00598 unneeded 
 
 
 
Social Interaction Graphs 
 
We obtained interaction graphs to cover three more or less unrelated social areas. The 
Enron Graph represents emails during the company’s financial crisis. The arXiv Graph 
denotes a collaboration network, mainly for high-energy physics, whose edges link 
electrical preprint co-authorship. Finally, the Wiki-Vote Graph depicts votes for 
Wikipedia moderators. As before, all three sets of data were obtained from the Stanford 
collection. 
 
As with the physical infrastructure graphs, social graphs kernelize so well that they can 
be solved easily by branching sequentially. There is no need for parallelism. In fact, the 
arXiv graph was solved completely through kernelization alone. It seems that low 
average degree again leads to a very effective application of the high degree rule in the 
complement. See Table 8. 
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Table 8. Computational experience with large social interaction graphs. Run times are 
reported in seconds. The graph derived from electronic preprints was solved completely 
during kernelization, and thus needed no branching at all. 
 
Graph Enron arXiv Wiki-Vote 
|V| 36692 12008 7115 
|E| 183831 118521 100656 
Density 0.00027 0.00164 0.00398 
Kernel Size 2276 240 2226 
Clique Size 20 239 17 
Sequential Branching 118.3 unneeded 111.1 
 
 
 
High-Throughput Biological Graphs 
 
We tried to focus on markedly different sorts of biological graphs, and ended up 
employing data about human proteomics, methylation and transcriptomics. PPI was 
created from a curated protein-protein interaction database. Colitis.98 was created using 
genomic methylation data from a study on Ulcerative Colitis while LRMS.8 was created 
from gene expression microarray data concerning Low-Risk Myelodysplastic Syndrome. 
Both data sets are publicly available on the Gene Expression Omnibus (GEO). The 
associated datasets are GSE27899 and GSE41130 respectively. For Colitis.98 a weighted 
graph was first created using methylation sites as vertices with edges weighted by p-
values of the Pearson correlation between the methylation levels. The same was done for 
LRMS.8 using genes and gene expression levels. In each case, the graph was then 
converted to an unweighted graph by removing all edges whose weights fall below a 
certain threshold (p = .98 and p = .8 respectively). 
As with our physical infrastructure and social interaction experiences, kernelization 
nearly solved PPI. The other two graphs, Colitis.98 and LRMS.8, were each left with a 
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fairly formidable kernel. Although effective parallel vertex cover algorithms have been 
tailored to such graphs in previous work [134, 135], it is notable here that, like in the 
cases of the Enron and Wiki-Vote graphs, the kernels produced were such that sequential 
branching finished in a matter of a very few minutes without the need for parallelism. See 
Table 9. 
 
Pseudo-Random Graphs 
 
We created a pair of pseudo-random graphs using standard random graph models, the 
Erdös-Rényi model [136] and the Watts-Strogatz model [137]. The Erdös-Rényi graph, 
ER_5k, was constructed using an edge density of 0.1. Each potential edge was either 
present or absent based on this probability. The Watts-Strogatz graph, WS_800, began 
with a regular ring lattice, where every vertex had degree 300. One endpoint of each edge 
was then randomly rewired with probability 0.2. We tried to use the Barabási-Albert 
preferential attachment model [138] for a third pseudo-random graph. Unfortunately, this 
simple model never yields a clique of size greater than x+1, where x is the number of 
edges connecting each new node to the existing graph. For instance, when x=2, we obtain 
a graph with a maximum clique of size 3. Such graphs and their complements are solved 
very quickly by standard clique and vertex cover implementations. We therefore chose to 
create the graph Norm_900 by choosing normally distributed random degrees for the 
vertices and then setting edges with uniform probability. 
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Table 9. Computational experience with large high-throughput biological graphs. Run 
times are reported in seconds. 
 
Graph PPI Colitis.98 LRMS.8 
|V| 9314 12755 14977 
|E| 39473 107205 178377 
Density 0.00091 0.00132 0.00159 
Kernel Size 344 2040 1795 
Clique Size 13 19 30 
Sequential Branching 0.75154 264.87 229.99 
 
 
 
The structure of these pseudo-random graphs seems to be such that some reasonable 
modicum of speedup is possible with our balanced tree search. In the case of ER_5k, 
speedup seems to have been limited by its low density. Both the Erdös-Rényi and the 
Watts-Strogatz models produce graphs whose degree distribution is roughly normal, with 
mean centered at the average degree of the graph. We will say more about this issue in 
the next section. See Table 10. 
 
Regularly Structured Graphs 
 
We loosely define regularly structured graphs to be those with a narrow degree range. 
The limiting case is of course truly regular graphs, whose vertices all have the same 
degree. In fact two of the graphs we tested, 5x50_C and 90_Cycle_C, are truly regular. 
The third, a subgraph of a Hamming graph, is highly but not truly regular, with vertex 
degrees in the range [247,270]. 5x50_C is the complement of the graph obtained by 
arranging 50 5-cliques in a circle and connecting the corresponding adjacent clique  
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Table 10. Computational experience with large pseudo-random graphs. Run times are 
reported in seconds. 
 
Graph ER_5k WS_800 Norm_900 
|V| 5000 800 900 
|E| 1250505 120000 158221 
Density 0.10006 0.37547 0.39110 
Kernel Size 5000 800 900 
Clique Size 7 26 20 
Sequential 
Branching 
7635 8894.45 13027.7 
Parallel Branching 4260 646.5 844.9 
 
 
 
vertices. 90_Cycle_C was constructed by starting with an even cycle, connecting its 
opposite vertices, then taking its complement. That is, beginning with a cycle of length n, 
with vertices labeled 0,1,2,...,n-1, add edges (0,n/2), (1, n/2 + 1), (2, n/2 + 2), ... , (n/2-1, 
n-1). Figure 24 illustrates this notion with an example for n = 10. 
 
Ham_9_4 was obtained as a 350-node subgraph of a standard Hamming graph, 
constructed using parameters n=9 and d=4. In such a graph, vertices are viewed as binary 
vectors of length n, and an edge is present if and only if the Hamming distance between 
the two vectors is greater than or equal to d.  
 
Because low and high degree vertices are absent, regularly structured graphs are 
notoriously difficult, and generally show no benefit whatsoever from kernelization. 
Moreover, such graphs tend to have topological symmetry and fill many branches of the  
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Figure 24. A regularly structured graph. 90_Cycle_C is the complement of this graph of 
order 90. 
 
 
 
search tree with near-optimal solutions. Thus, many branches must be fully explored. 
Ironically, however, the very topological symmetry that makes such instances difficult 
makes them amenable to parallelization. In this study, regularly structured graphs 
produced the best speedup we see. 
 
We emphasize that this efficiency is relative. These are not linear-time systolic problems 
that easily yield linear speedups. Instead, these are NP-compete problems. Their kernels 
require exhaustive search. They generally incur several penalties with respect to 
communication overhead, non-uniform memory access and so forth. Thus, we must 
temper our enthusiasm and lower our expectations. Nevertheless, the efficiencies we see 
are respectable for problems of this ilk. See Table 11.  
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Table 11. Computational experience with large regularly structured graphs. Run times are 
reported in seconds. 
 
Graph 5x50_C 90_Cycle_C Ham_9_4 
|V| 250 180 350 
|E| 6500 15390 44842 
Density 0.75155 0.95531 0.73421 
Kernel Size 250 180 350 
Clique Size 5 90 18 
Sequential Branching 369 3802 15686 
Parallel Branching 23.75 236 1011.1 
 
 
 
Parallel Utilization 
 
There seem to be at least two major factors influencing the relative effectiveness of our 
parallel branching strategy: average vertex degree and vertex degree distribution. If the 
average vertex degree in the complement is very high, then each time a vertex is added to 
a possible cover in a left branch, its many neighbors will be added to a possible cover in 
the right branch. This may result in a highly unbalanced search tree, and thus poor 
parallel speedup. In Table 4, for example, we see that the density of ER_5k is 0.10006. 
Therefore the average degree in its complement is very high, and we witnessed only a 
modest speedup. In order to produce a balanced search tree without excessive load 
balancing, it seems from these experiments that the complement must exhibit a relatively 
tight vertex degree distribution about the mean, with the mean itself relatively low. This 
is precisely the case with the regularly structured graphs and with Norm_900. 
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We also note that graph size will naturally limit the scalability we can expect to see. On 
Ham_9_4, for example, we saw speedups up to 48 cores that then leveled out quickly. On 
the other hand, we were able to scale up to 720 cores before leveling out on the larger 
Norm_900 graph. See Figures 25 and 26. 
 
Summary 
 
We have studied the significance of kernelization versus branching when solving the 
classic vertex cover decision problem on large graphs from five different application 
domains. For some, we found that kernelization alone sufficed. For others, we found that 
kernelization and branching could work together to find solutions quickly. And yet for 
others, we discovered that kernelization fails completely, leaving branching to solve the 
entire problem. 
 
An important hallmark of problems amenable to kernelization appears to be a 
complement whose degree structure follows an inverse power law distribution. Such a 
graph may benefit from reductions by the high degree rule, while its compute kernel may 
have a similar distribution, which in turn increases the effectiveness of interleaving. Our 
physical infrastructure, social communication, and high throughput biological graphs all 
have this type of structure. See, for example, Figure 27. On the other hand, graphs that do 
not kernelize were either pseudo-regular or those whose complements’ degree 
distributions clustered tightly about a mean value low enough to avoid the high degree 
rule. See Figure 28.  
 
Turning now to branching, graphs benefiting most from our parallel strategy were those 
that had a relatively tight vertex degree distribution about a relatively low mean. It 
remains to be seen whether different branching strategies will behave in markedly  
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Figure 25. Speedup for Ham_9_4. Relatively small graph size limits scalability.  
 
 
 
Figure 26. Speedup for Norm_900. Larger graphs provide enhanced opportunities for 
scalability. 
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Figure 27. Degree distribution of Enron’s complement. Kernelization and sequential 
branching proved most effective on graphs whose complements show an inverse power 
law degree distribution. 
 
 
 
 
Figure 28. Degree distribution of ER_5k. A normalesque distribution combined with a 
sufficiently low mean reduces the benefits of kernelization.  
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different ways. In previous work, it has been shown that parallel vertex cover can be 
tailored to transcriptomic and other specific classes of graphs [128, 130, 135]. For a given 
branching strategy, it might prove fruitful to trace through numerous search trees in an 
attempt to identify cases for which the strategy is ideal and those for which it fails. 
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CHAPTER FIVE CONCLUSIONS AND DIRECTIONS FOR 
FURTHER RESEARCH 
 
We have examined both the application and efficiency of graph-theoretical algorithms to 
the study of complex networks. We considered the use of exact solvers for two NP-
complete problems, primarily dominating set and clique, and their utility in solving 
difficult biological problems. This work required novel approaches to algorithm 
development, as well as implementation and testing on a wide variety of publicly 
available data. We also detailed our efforts to analyze the interplay between the two 
critical components of fixed parameter tractable implementations. In this final section, we 
review the primary contributions of this dissertation and avenues for further research. 
 
Summary of Contributions 
 
The effort has focused on the development of combinatorial tools for the analysis of 
complex networks. Its primary contributions are the adaptation of a graph-based 
toolchain for biomarker discovery to DNA methylation data, with improvements to the 
method, a novel method for identifying subtypes of complex disease from gene 
expression data using the paraclique algorithm, and an empirical study of the relative 
significance of kernelization compared to branching on different graph classes for the 
vertex cover problem on parallel platforms. Although the application focus in the 
development of these algorithms was mainly on microbiology, their foundation is set in 
the mathematical abstraction of graph theory. As such, their applications transfer easily to 
other domains. Together, these results provide algorithmic advances for the study of 
complex networks as well as insight into the design of efficient algorithms through the 
use of fixed parameter tractability. 
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Originally, the graph-based toolchain for biomarker discovery was designed for gene 
expression data. Our contributions expanded and improved it in several key ways: 
• Its adaptation to methylation data required scaling to a ten-fold increase in the 
number of variables. 
•  We introduced a tuning factor to address initial runs not identifying sites with 
positive merit scores. 
•  We employed an exact rather than an approximate dominating set filter. 
•  We added a neural net classifier to the toolchain. 
We then tested the improved method on eight data sets obtained from GEO representing a 
variety of complex human disease. With the exception of chronic fatigue associated with 
Sjogren’s syndrome, our method performed well in all cases. For instance, in breast 
cancer data, it identified a set of only five methylation sites that the neural net classifier 
used to discriminate between tumor and healthy tissue samples with an accuracy of 0.96. 
We note that our method is of course reliant on the data provided. Methylation 
biomarkers may be observable in one type of tissue, but not others. For example, the 
inability to identify markers in the Sjogren’s syndrome data may indicate the absence of a 
link between associated chronic fatigue and methylation levels, or only that such markers 
are not carried in peripheral blood.  
 
The method we developed for using the paraclique algorithm to identify putative 
subgroups in gene expression data has several key features:  
• It reduces the effects of confounding factors by introducing an initial filtering 
step when accompanying control data is available. 
•  It transposes the correlation matrices typically used in a gene network analysis, 
computing sample-sample correlations to which a threshold is applied to build a 
graph. 
•  It then applies the paraclique algorithm to identify dense subgraphs representing 
potential subtypes. 
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We applied the method to twelve publicly available data sets obtained from GEO 
representing a range of human disease. Our method identified putative subtypes in ten of 
those cases. In the other two cases, we feel that either there is no discernable molecular 
subtype associated with the disease, or perhaps more likely, the available data set was too 
small to allow its discovery. To help validate the putative subtypes produced by our 
method, we conducted a literature review for the involvement of genes differentially 
expressed between paracliques having known biological relevance. We also conducted 
GO enrichment to determine whether the method differentiated between known 
molecular subtypes. Despite our efforts at validation, we recognize that this work is 
somewhat limited by a lack of ground truth. Further investigation into the biological role 
of the genes driving the separation of our putative subtypes is needed.  
 
To investigate the relative significance of kernelization compared to branching in a 
parallel FPT version of a vertex cover solver, we implemented several reduction rules, 
including the low degree, high degree and full degree rules. We performed extensive 
testing on a variety of large graphs with different structural characteristics drawn from 
five classes. The tests were ran on the Hopper machine at the NERSC facility, at the time 
the 16th fastest supercomputer for academic research in the world. Our testing revealed 
wide disparities between classes of graphs. Graphs whose degree structure follow a 
power law or inverse power law distribution can be almost completely solved with 
kernelization, while pseudo-regular graphs gain little benefit from kernelization, and must 
rely entirely on branching. The parallel speedup obtained by our algorithm relies greatly 
on the structure of the input graph. Potential steps to reduce this dependence and improve 
scalability include investigating alternative branching strategies and improving load 
balancing. 
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Possible New Directions for Future Work 
 
The work presented in this dissertation represents a stepping stone in the path to 
harnessing the power of exact solutions to NP-complete graph problems for the practical 
exploration of large, complex networks. As such, it leaves open a variety of avenues for 
further research. 
 
The work on methylation biomarker discovery could potentially form the basis for the 
analysis of other types of epigenetic data. Given the success of using our dominating set 
filter for feature selection, future work is warranted to investigate potential synergies 
between classical graph algorithms and traditional machine learning approaches. 
Additionally, work remains to be done improving the current state of the art 
implementations of dominating set. 
 
The subtyping work can also be applied to other types of data rather than gene 
expression, such as epigenetic data. In particular, it would be interesting to see how well 
the approach adapts to categorical data. An open area is the development of automatic 
validation metrics to judge the “goodness” of putative subtypes. 
 
Finally, the work on FPT vertex cover in chapter four opens several paths forward. 
Perhaps most promising would be the development of structural metrics that predict 
scalability and performance of various vertex cover/clique finders. With such metrics in 
hand, one could then design a targeted solver that would select the best approach based 
on the input graph. As we observed, satisfactory parallel speedup in our current 
implementation often depends on the structure of the input graph. As such, much work 
remains in developing parallel graph algorithms for problems such as vertex cover that 
require highly randomized memory access.  
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